{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:56:53Z","timestamp":1761541013671},"reference-count":29,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":1857,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1097\/jto.0b013e3181ee820c","type":"journal-article","created":{"date-parts":[[2010,9,28]],"date-time":"2010-09-28T09:52:06Z","timestamp":1285667526000},"page":"1815-1820","source":"Crossref","is-referenced-by-count":19,"title":["Randomized, Double-Blinded, Multicenter, Phase II Study of Pemetrexed, Carboplatin, and Bevacizumab with Enzastaurin or Placebo in Chemona\u00efve Patients with Stage IIIB\/IV Non-small Cell Lung Cancer: Hoosier Oncology Group LUN06-116"],"prefix":"10.1016","volume":"5","author":[{"given":"Erin M.","family":"Casey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wael","family":"Harb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Bradford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Bufill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sreenivasa","family":"Nattam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyoti","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane E.","family":"Latz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaochun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingwei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasser","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0b013e3181ee820c_bib1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"10.1097\/JTO.0b013e3181ee820c_bib2","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/bmj.311.7010.899","article-title":"Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group","volume":"311","year":"1995","journal-title":"BMJ"},{"key":"10.1097\/JTO.0b013e3181ee820c_bib3","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1200\/JCO.2008.17.7162","article-title":"Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials","volume":"26","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181ee820c_bib4","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/thx.2003.020164","article-title":"Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life","volume":"59","author":"Spiro","year":"2004","journal-title":"Thorax"},{"key":"10.1097\/JTO.0b013e3181ee820c_bib5","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1002\/cncr.21480","article-title":"Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer","volume":"104","author":"Zinner","year":"2005","journal-title":"Cancer"},{"key":"10.1097\/JTO.0b013e3181ee820c_bib6","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1158\/1078-0432.690.11.2","article-title":"Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial","volume":"11","author":"Scagliotti","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3181ee820c_bib7","first-page":"3217","article-title":"A phase III study by the Norwegian Lung Cancer Group: pemetrexed plus carboplatin vs. gemcitabine plus carboplatin as firstline chemotherapy in advanced non-small cell lung cancer","volume":"27","author":"Gronberg","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0b013e3181ee820c_bib8","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181ee820c_bib9","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1200\/JCO.2005.18.853","article-title":"Angiogenesis and lung cancer: prognostic and therapeutic implications","volume":"23","author":"Herbst","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181ee820c_bib10","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1054\/bjoc.1999.1129","article-title":"Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer","volume":"82","author":"O'Byrne","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1097\/JTO.0b013e3181ee820c_bib11","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.lungcan.2005.09.005","article-title":"Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood","volume":"51","author":"Bremnes","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3181ee820c_bib12","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/ncponc0403","article-title":"Lessons from phase III clinical trials on anti-VEGF therapy for cancer","volume":"3","author":"Jain","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1097\/JTO.0b013e3181ee820c_bib13","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e3181ee820c_bib14","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","article-title":"Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil","volume":"27","author":"Reck","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181ee820c_bib15","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1200\/JCO.2008.20.8181","article-title":"Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer","volume":"27","author":"Patel","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181ee820c_bib16","first-page":"1375","article-title":"Elevated protein kinase C betaII is an early promotive event in colon carcinogenesis","volume":"61","author":"Gokmen-Polar","year":"2001","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e3181ee820c_bib17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1634\/theoncologist.7-1-17","article-title":"Targeting protein kinase C: new therapeutic opportunities against high-grade malignant gliomas?","volume":"7","author":"da Rocha","year":"2002","journal-title":"Oncologist"},{"key":"10.1097\/JTO.0b013e3181ee820c_bib18","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nm0102-68","article-title":"Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning","volume":"8","author":"Shipp","year":"2002","journal-title":"Nat Med"},{"key":"10.1097\/JTO.0b013e3181ee820c_bib19","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.1158\/0008-5472.CAN-05-0071","article-title":"The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts","volume":"65","author":"Graff","year":"2005","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e3181ee820c_bib20","first-page":"603","article-title":"Enzastaurin and pemetrexed exert synergistic antitumor activity in thyroid cancer cell lines in vitro","volume":"43","author":"Oberschmidt","year":"2005","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1097\/JTO.0b013e3181ee820c_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/S1359-6349(09)71792-6","article-title":"Pemetrexed in combination with cisplatin or carboplatin in the first line therapy of locally advanced or metastatic non-small cell lung cancer: a randomized, two-arm, parallel, open-label, multicentric phase II study","volume":"7","author":"Schuette","year":"2009","journal-title":"Eur J Cancer Suppl"},{"key":"10.1097\/JTO.0b013e3181ee820c_bib22","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1200\/JCO.2007.14.3685","article-title":"Enzastaurin, an oral serine\/threonine kinase inhibitor, as second- or third-line therapy of non-small cell lung cancer","volume":"26","author":"Oh","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181ee820c_bib23","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.8037","article-title":"Final results of a randomized phase II trial of pemetrexed (P) + carboplatin (Cb) +\/\u2212 enzastaurin (E) versus docetaxel (D) + Cb as first-line treatment of patients (pts) with stage IIIB\/IV non-small cell lung cancer (NSCLC)","volume":"27","author":"Obasaju","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181ee820c_bib24","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1200\/JCO.2007.12.3026","article-title":"Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer","volume":"25","author":"Herbst","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181ee820c_bib25","author":"Hainsworth","year":"2008"},{"key":"10.1097\/JTO.0b013e3181ee820c_bib26","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2009.27.15_suppl.8015","article-title":"S0536: Carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC): a SWOG phase II study","volume":"27","author":"Gandara","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181ee820c_bib27","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1200\/JCO.2007.10.8332","article-title":"Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity","volume":"26","author":"Azad","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181ee820c_bib28","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2008.26.15_suppl.5011","article-title":"Update results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC)","volume":"26","author":"Sosman","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181ee820c_bib29","unstructured":"BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC). Protocol ID: NCT00533585. Available at: clinicaltrials.gov."}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415318414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415318414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T14:24:26Z","timestamp":1685802266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086415318414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S1556086415318414"],"URL":"https:\/\/doi.org\/10.1097\/jto.0b013e3181ee820c","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}